pharma · Focal Segmental Glomerulosclerosis · Immunoglobulin A Nephropathy (IgAN) · TVTX
Travere Therapeutics
Travere Therapeutics patent portfolio — 1 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 3611 Valley Centre Dr, Suite 300, San Diego, California 92130, US
- Founded
- 2020
- Employees
- 506
- Programs
- 13
- Drugs
- 9
- Patents
- 1
Travere Therapeutics patents
1 pharmaceutical patents indexed for Travere Therapeutics. 0 expire within 24 months.
Travere Therapeutics has 1 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
Frequently asked questions
How many patents does Travere Therapeutics have?
1 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Travere Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.